(Q35109750)

6 August 2017

1 reference

title

Proteasome inhibition: a new anti-inflammatory strategy (English)

1 reference

6 August 2017

0 references

Peter J Elliott

1

1 reference

PubMed ID

12700891

6 August 2017

Thomas Matthias Zollner

series ordinal

2

1 reference

PubMed ID

12700891

6 August 2017

Wolf-Henning Boehncke

series ordinal

3

1 reference

6 August 2017

26 March 2003

1 reference

Journal of Molecular Medicine

6 August 2017

1 reference

6 August 2017

81

1 reference

6 August 2017

235-245

1 reference

6 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s00109-003-0422-2

6 August 2017

0 references

cites work

The ubiquitin-proteasome pathway: on protein death and cell life

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Proteasomes: multicatalytic proteinase complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

New insights into proteasome function: from archaebacteria to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Roles of ubiquitin-mediated proteolysis in cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

The ubiquitin-proteasome pathway and proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Proteasome inhibitors: from research tools to drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

The proteasome: a new target for novel drug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

A giant protease with potential to substitute for some functions of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Modeling of the binding mode of a non-covalent inhibitor of the 20S proteasome. Application to structure-based analogue design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Possible new role for NF-kappaB in the resolution of inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Hematologic malignancies: new developments and future treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

The proteasome: a novel target for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Neuroprotection in cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Brain ischemia and reperfusion: molecular mechanisms of neuronal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

The NF-kappa B and I kappa B proteins: new discoveries and insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Arthritis in rats after systemic injection of streptococcal cells or cell walls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Regulation of rheumatoid synoviocyte proliferation by endogenous p53 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Inhibition of nuclear factor-kappaB activation un-masks the ability of TNF-alpha to induce human eosinophil apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Proteasome inhibition: A novel mechanism to combat asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Protection against experimental autoimmune encephalomyelitis by a proteasome modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Psoriasis and bacterial superantigens--formal or causal correlation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Inflammatory skin diseases, T cells, and immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Psoriasiform architecture of murine epidermis overlying human psoriatic dermis transplanted onto SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Not just research tools--proteasome inhibitors offer therapeutic promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Dual roles of proteasome in the metabolism of presenilin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Proteasome subunits, low-molecular-mass polypeptides 2 and 7 are hyperexpressed by target cells in autoimmune thyroid disease but not in insulin-dependent diabetes mellitus: implications for autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Inhibition of hepatitis B virus replication by interferon requires proteasome activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

The ubiquitin-proteasome pathway: review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

PDTC and Mg132, inhibitors of NF-kappaB, block endotoxin induced vasodilation of isolated rat skeletal muscle arterioles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-003-0422-2

Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid.

21 January 2018

1 reference

12 December 2020

Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine

1 reference

12 December 2020

Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury

1 reference

12 December 2020

Leucocyte-endothelial adhesion molecules and their role in bronchial asthma and allergic rhinitis

1 reference

12 December 2020

Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme

1 reference

12 December 2020

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

1 reference

12 December 2020

The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs

1 reference

12 December 2020

Is nuclear factor-kappaB a good treatment target in brain ischemia/reperfusion injury?

1 reference

12 December 2020

Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia

1 reference

12 December 2020

Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease: toxins, mediators, and modulators of gene expression.

1 reference

12 December 2020

Selective proteasome inhibitors: modulators of antigen presentation?

1 reference

12 December 2020

Proteasome inhibitors: complex tools for a complex enzyme

1 reference

12 December 2020

PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation

1 reference

12 December 2020

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies

1 reference

12 December 2020

Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model

1 reference

12 December 2020

1alpha,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice

1 reference

12 December 2020

Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells

1 reference

12 December 2020

Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis

1 reference

12 December 2020

Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model.

1 reference

12 December 2020

Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart

1 reference

12 December 2020

Inflammation in asthma: the cornerstone of the disease and target of therapy

1 reference

12 December 2020

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

12 December 2020

A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.

1 reference

12 December 2020

Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-kappaB activation in drug resistance.

1 reference

12 December 2020

Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis

1 reference

12 December 2020

Blockade of NF-kappaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease?

1 reference

12 December 2020

Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB

1 reference

12 December 2020

Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519

1 reference

12 December 2020

10.1007/S00109-003-0422-2

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12700891